Targeting of type I interferon in systemic autoimmune diseases - Test2 - elhamkhani - TriplyDB

Targeting of type I interferon in systemic autoimmune diseases

Targeting of type I interferon in systemic autoimmune diseases

http://www.wikidata.org/entity/Q34451758

about

Identification of Candidate Predictors of Lupus Flare Multiple Roles for B-Lymphocytes in Sjogren's Syndrome Cause and consequences of the activated type I interferon system in SLE Increased CD40 Expression Enhances Early STING-Mediated Type I Interferon Response and Host Survival in a Rodent Malaria Model.Siglec1 suppresses antiviral innate immune response by inducing TBK1 degradation via the ubiquitin ligase TRIM27.Parsing the Interferon Transcriptional Network and Its Disease Associations Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions.Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.The expanding regulatory network of STING-mediated signaling.The molecular basis for differential type I interferon signaling.Immune Diseases Associated with TREX1 and STING Dysfunction.Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome.Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease.Negative regulation of MAVS-mediated innate immune response by ASC.Epstein-Barr virus infection and type I interferon signature in patients with systemic lupus erythematosus.Associations between type I interferon and antiphospholipid antibody status differ between ancestral backgrounds.Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus.Systemic lupus erythematosus.Editorial: Interferon-Targeted Therapy for Systemic Lupus Erythematosus: Are the Trials on Target?Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.

P2860

Q26795372-ACBC9E8A-4B78-4849-86F4-D0B8F4121D86 Q28068695-EC6F8F90-032A-492D-9A12-659F235E82EC Q28075268-FB10BCAA-FF4D-4D5B-A521-7C64886672B0 Q36157771-2A6A3B1A-C7C2-4DEE-9BF2-A9557D2853E7 Q36293523-F2B63B9A-675A-4A9C-B98E-EF0F908E4921 Q36550657-9B1C79DA-90EA-4E85-8CE2-B20FC51FC7C4 Q37541469-43925A8A-A0F4-45D0-B213-419A6E4B0693 Q37556634-2108BEA6-1453-4E4A-AA70-238C7DF1226F Q37633408-DFBFCD4D-0F6A-4C69-B629-C928689C2BCD Q38879970-3AC9FAD0-7161-4CCD-8FFB-767819107ECB Q38896335-28B0AC2E-5CE5-4C1E-BE41-DA38AE976A83 Q39176574-2ED7136C-82EF-4E7A-AE4C-FB3D76AA40F1 Q39285868-BEECC49D-91A0-4BEB-A136-2F080A16638C Q39586997-60162CEC-8F8C-47C1-AE35-12C13E8FA9B2 Q40513722-9206F14F-B4CB-42EE-B574-D46A83DDF932 Q47217292-0903528D-7A6E-4980-B3D4-40155CF3C5AB Q47552993-A830B038-EDDC-4C14-B4C8-5E89FBF62176 Q48129323-0A299E4A-C29B-4419-A654-C066A00EBD12 Q49830970-10341695-4D6C-4815-9BF6-F35573DBC799 Q50848358-BC7EE3A6-7636-4476-BBEF-4153C99DDF3E Q53675008-6F687C4D-AE17-4BF2-A8A9-E9405A8A8E1A Q55100613-FCCE3265-B379-497B-834B-12A43D91148A

P2860

Targeting of type I interferon in systemic autoimmune diseases

http://www.wikidata.org/entity/Q34451758

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeting of type I interferon in systemic autoimmune diseases

@ast

Targeting of type I interferon in systemic autoimmune diseases

@en

Targeting of type I interferon in systemic autoimmune diseases

@nl

type

label

Targeting of type I interferon in systemic autoimmune diseases

@ast

Targeting of type I interferon in systemic autoimmune diseases

@en

Targeting of type I interferon in systemic autoimmune diseases

@nl

prefLabel

Targeting of type I interferon in systemic autoimmune diseases

@ast

Targeting of type I interferon in systemic autoimmune diseases

@en

Targeting of type I interferon in systemic autoimmune diseases

@nl

P1433

Q34451758-30F940EF-1C01-46F0-A8A4-2C9D1A78000E

P1476

Q34451758-5D312BD7-30F3-4478-94BD-27EA9375F347

P2093

Q34451758-732B5AA7-BD2D-4E4E-BD89-65D1DDB645B9

Q34451758-A31B7498-AD78-483C-8648-8AFA62D150C1

Q34451758-B30C6805-A7AB-4523-A509-533D314A86A3

P2860

Q34451758-03DC7554-0066-4330-9879-005D157D9682

Q34451758-04A003AD-E02B-40CD-A7DA-B421305C26F9

Q34451758-0A9674D3-CA05-4123-976A-9EE187065094

Q34451758-0C8E2E0F-F6AE-411C-920F-62DB5086E1FE

Q34451758-0CDA7DF5-47AE-4D99-9224-09DE5ED04D91

Q34451758-1443C10F-B13A-47DE-8AAF-1B136C699496

Q34451758-1990BD42-F3A5-48EB-9C58-C687CAE4A38B

Q34451758-1D3D5464-F47A-497C-B5B6-D6EC1F716CF6

Q34451758-1E3568F6-035F-4B62-ABBD-0BD372BCB7A1

Q34451758-1EF26219-1A4B-4DB7-875E-D211F4E6EE3E

P304

Q34451758-4A4E9414-803C-48E0-94AA-65B3D8B87FFC

P31

Q34451758-03D6464E-A9EC-48AF-A89C-94C908BD4292

P356

Q34451758-4174A987-D85A-4F93-AB0B-01FC6F155446

P433

Q34451758-5A223F74-99F3-45E1-BCB7-7280C6563DB1

P478

Q34451758-5815A309-B9C4-49B7-8823-2D2885DA158F

P577

Q34451758-8648F9F9-5AEE-4BB3-92BE-2D50A6492A81

P698

Q34451758-9A93DD3D-6E20-4DFA-84B5-2890D51A470A

P932

Q34451758-50036E2C-6AF7-4191-A7BE-312EE8605AC1

P356

J.TRSL.2014.10.005

P1433

Translational Research

P1476

Targeting of type I interferon in systemic autoimmune diseases

@en

P2093

Kyriakos A Kirou

http://www.w3.org/2001/XMLSchema#string

Mary K Crow

http://www.w3.org/2001/XMLSchema#string

Mikhail Olferiev

http://www.w3.org/2001/XMLSchema#string

P2860

Trex1 prevents cell-intrinsic initiation of autoimmunity

Microarray analysis of gene expression in lupus

Innate immune responses and rapid control of inflammation in African green monkeys treated or not with interferon-alpha during primary SIVagm infection

Kinetics of myeloid dendritic cell trafficking and activation: impact on progressive, nonprogressive and controlled SIV infections

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature

Interferons, interferon-like cytokines, and their receptors

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

Interferon alpha on NZM2328.Lc1R27: enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failure

P304

296-305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRSL.2014.10.005

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25468480

http://www.w3.org/2001/XMLSchema#string

P932

4306610

http://www.w3.org/2001/XMLSchema#string